whitepaper
Cell and Gene Therapy Containment
Overcoming Challenges in Cell and Gene Therapy Containment.
List view / Grid view
Cell-Based Assays for Screening
news
Bioavailability tests could improve personalised medicine approaches, study shows
Researchers have demonstrated that bioavailability tests in patients to reveal anti-drug antibody levels could aid personalised medicine.
article
Single-cell analysis techniques: advances enabling early diagnosis of genetic diseases
In this article Pramod Kumar, a Senior Research Analyst (Healthcare) at P&S Intelligence, explores how single-cell analysis techniques are used for both pharmaceutical R&D and clinical, diagnostic applications.
news
Device offers inexpensive and quick screening of diseases
A multidisciplinary research team have developed a portable device to accurately and quickly screen people for diseases...
news
Radiance could be the key to faster viral detection
Viruses explored through Radiance, an instrument designed to improve the process of analysis, ensures quick and efficient viral detection...
news
Sensitive new assay detects hepatitis B infection in single liver cells and serum
Technique measuring the cccDNA marker may allow earlier detection of hepatocellular carcinoma in patients…
news
Crizotinib-radiation therapy combination may help preserve hearing in NF2
Adding the targeted cancer therapy drug crizotinib to radiation therapy for tumours associated with the genetic disorder neurofibromatosis 2 may reduce the hearing damage that can be exacerbated by radiotherapy...
news
Rapidly develop drugs targeting Interleukins with new PathHunter® cell-based assays from DiscoveRx
DiscoveRx Corporation, the leading supplier of innovative cell-based assays and services for drug discovery and development, announces the expansion of its PathHunter® cell-based assays portfolio with the release of PathHunter Interleukin cell-based assays.
article
Cell-based assays for protein-protein interactions
22 October 2013 | By Mark Wade, Center for Genomic Science of IIT@SEMM
Protein-protein interactions (PPI) form the backbone of all cellular signalling networks, and aberrant PPI contribute to the pathology of several diseases. Thus, strategies to identify PPI modulators are expected to be therapeutically beneficial. However, there are very few examples of clinically approved PPI modulators, reflecting the difficulties of identifying effective…
article
GPCRs: Cell based label-free assays in GPCR drug discovery
20 August 2013 | By Niklas Larsson, Linda Sundström, Erik Ryberg and Lovisa Frostne (AstraZeneca)
G protein-coupled receptors are one of the major classes of therapeutic targets for a broad range of diseases. The most commonly used assays in GPCR drug discovery measure production of second messengers such as cAMP or IP3 that are the result of activation of individual signalling pathways. Such specific assays…
article
Stem Cells In-Depth Focus 2013
In this Stem Cells In-Depth Focus: The promise held by induced pluripotent stem cells for research and regenerative medicine; Workshop preview – Cell based assays for screening; Cardiac stem cells; Stem Cells Roundtable...
news
Collaboration to accelerate drug discovery in cardiac disease announced
19 March 2013 | By InvivoSciences Inc.
Torrey Pines Institute for Molecular Studies and InvivoSciences collaborate to accelerate drug discovery in cardiac disease...
article
Practical Workshop – Biochemical Assays for Screening
21 February 2013 | By Sheraz Gul, Head of Biology at European ScreeningPort, Hamburg, Germany
Recent years have witnessed an expansion in the disciplines encompassing drug discovery outside the pharmaceutical industry. This is most notable with a significant number of universities worldwide that now host infrastructure such as compound libraries and automated screening centres[1-3]. An archetypal small molecule drug discovery project will aim to identify…
